Patent Grant
12343383
This application is a 35 U.S.C. § 371 National Stage application of International Application PCT/EP2020/069512 (WO2021009027), filed Jul. 10, 2020, which claims priority to European Patent Application 19185958.6, filed Jul. 12, 2019.
The present invention relates to the field of pharmaceutical compositions of acylated insulin, and method for using such compositions in the treatment of diseases. Also, the present invention relates to the field of manufacture of such pharmaceutical compositions.
Currently, the treatment of diabetes, both type 1 diabetes and type 2 diabetes, relies to an increasing extent on the so-called intensive insulin treatment. According to this regimen, the patients are treated with multiple daily insulin injections comprising one or two daily injections of a long acting insulin to cover the basal insulin requirement supplemented by bolus injections of a rapid acting insulin to cover the insulin requirement related to meals.
Long acting insulin compositions are well known in the art. Thus, one main type of long acting insulin compositions comprises injectable aqueous suspensions of insulin crystals or amorphous insulin. In these compositions, the insulin compounds utilized typically are protamine insulin, zinc insulin or protamine zinc insulin. Other long acting insulin compositions are e.g. Lantus® and Tresiba® having protracted profiles of action as compared to human insulin.
Crystallized insulin whether this being protamine crystallized when injecting it or whether the insulin composition crystallizes upon injection do have a number of drawbacks such as potential immunogenic reactions, homogeneity, tissue irritation and reactions and the like.
Another type of long acting insulin composition is solutions having a pH value below physiological pH from which the insulin will precipitate because of the rise in the pH value when the solution is injected. A drawback with these solutions is that the particle size distribution of the precipitate formed in the tissue on injection, and thus the release profile of the medication, depends on the blood flow at the injection site and other parameters in a somewhat unpredictable manner. A further drawback is that the solid particles of the insulin may act as a local irritant causing inflammation of the tissue at the site of injection.
Insulin is a 51 amino acid peptide hormone produced in the islets of Langerhans in the pancreas. Its primary function, acting as a monomer, is to facilitate the transport of glucose molecules across the cell membranes of adipose and muscle tissue by binding to and activating a transmembrane receptor.
A distinctive property of insulin is its ability to associate into hexamers, in which form the hormone is protected from chemical and physical degradation during biosynthesis and storage. X-ray crystallographic studies on insulin show that the hexamer consists of three dimers related by a 3-fold axis of rotation. These dimers are closely associated through the interaction of two zinc ions at its core positioned on the 3-fold axis.
When human insulin is injected into the subcutis in the form of a high-concentration pharmaceutical formulation it is self-associated, and here dissociation into monomers is relatively slow. Hexamers and dimers of insulin are slower to penetrate capillary wall than monomers.
Zinc and phenolic additives are regularly used in therapeutic insulin preparations to promote hexamer formation as a precaution against degradation during storage. In this form, however, the action of injected insulin is delayed while the hexamers diffuse through the subcutis and dissociate into dimers and monomers.
The strength of insulin formulations is described in units (U) where one unit corresponds to 0.035 mg human insulin. Hence, a 100 U/ml human insulin formulation has a concentration of 3.5 mg/ml human insulin. Insulin degludec (NεB29-hexadecandioyl-γ-Glu-(desB30) human insulin) is commercially available as a 100 U/ml product as well as a 200 U/ml product.
Formulations of insulin are usually prepared by dissolving insulin in a small volume of water under acidic conditions. Zinc is then added to the formulation followed by a neutralisation and addition of preservatives like phenol and m-cresol. Concentrated insulin formulations, however, tend to be unstable upon storage and use, and just as important the PK profile changes with the insulin concentration.
WO2008/132224 discloses pharmaceutical composition comprising spray-dried insulin to make highly concentration insulin solutions for the treatment of diabetes.
WO2007/074133 discloses pharmaceutical composition comprising insulin degludec.
It is advantageous to have concentrated insulin formulations which are stable during storage and use. Such concentrated formulations would require less frequent change of disposable injection pen, and less frequent change of cartridge in durable injection devices. Also, the substantial development within injection devices in many cases require insulin compositions which are highly concentrated.
When the insulin concentration in insulin formulations is increased, there is a general tendency for the pharmacokinetic profile to be altered. More specifically, for a given dose of the insulin, the Cmax and AUC (bioavailability) tend to decrease when the insulin concentration in the formulation is increased. The change of pharmacokinetic properties when scaling the insulin concentration is a challenge to insulin products which typically go into different administration devices where different insulin concentrations are desired.
The present invention is related to certain pharmaceutical compositions of NεB29-hexadecandioyl-γ-Glu-(desB30) human insulin which solves the problems of the prior art.
It has surprisingly been found that high concentration, soluble insulin formulations can be made which have a PK profile substantially similar to a corresponding regular U200 product, while still being stable during storage and in-use.
Hence, in a first aspect the present invention provides a soluble insulin preparation comprising:
In a first embodiment of the invention the concentration of said zinc ions is from 5.0 Zn/6Ins to 5.5 Zn/6Ins.
In another embodiment of the invention the concentration of said zinc ions is from 5.0 Zn/6Ins to 6.0 Zn/6Ins.
In another embodiment the soluble insulin preparation comprises niacinamide in a concentration from 110 mM to 220 mM.
In another embodiment the soluble insulin preparation has a pH in the range from 7.4 to 7.8.
In another embodiment the soluble insulin preparations further comprise a phenolic preservative or a mixture of phenolic preservatives.
In another embodiment said phenolic preservative or mixture of phenolic preservatives is a mixture of phenol and m-cresol.
In another aspect the present invention provides a method of reducing the blood glucose level in a mammal by administering to a subject in need of such treatment a therapeutically effective dose of a soluble insulin preparation according to the present invention.
With the present invention it is possible for a person with diabetes to switch between e.g. a U200 formulation and a U500 formulation of NεB29-hexadecandioyl-γ-Glu-(desB30) human insulin without adjusting the dose.
It is also now possible for an individual who need very high doses of basal insulin, e.g. in excess of 160 U/day, to achieve this with a single daily dose.
Furthermore, since a typical insulin pen or cartridge typically contains 3 mL, there will be much more than 600 U in a single pen or cartridge, e.g. 1500 U for a U500 product, which means that the pen or cartridge need replacement less frequently. Also, the person will not as often have to split the dose when the pen or cartridge is nearly used up.
In a first aspect the present invention provides a soluble insulin preparation comprising:
For insulin preparations the concentration of insulin is typically given in units per milliliter, U/mL For NεB29-hexadecandioyl-γ-Glu-(desB30) human insulin 100 units (100 U) is the equivalent of 3.66 mg or 600 nmol of NεB29-hexadecandioyl-γ-Glu-(desB30) human.
It is also typical for insulin preparation comprising zinc to state the zinc concentration relative to the concentration of insulin calculated as hexamers, i.e. insulin concentration divided by 6. This molar ratio is termed “Zn/6Ins”, i.e. describing the relative molar concentration of zinc to one sixth of the insulin concentration.
When the insulin concentration in insulin formulations is increased, there is a general tendency for the pharmacokinetic profile to be altered. More specifically, for a given dose of the insulin, the Cmax and AUC (bioavailability) tend to decrease when the insulin concentration in the formulation is increased. This means that the glucose lowering effect of a U500 formulation will be less than that of a U200 formulation even though the same amount of insulin is administered. Hence, the two formulations will therefore not be bioequivalent.
This lack of scalability is a challenge for insulin preparations since insulins go into several different administration devices for which different concentrations of insulin is highly desirable.
The present inventors have found that for soluble preparations of NεB29-hexadecandioyl-γ-Glu-(desB30) human insulin the addition of citrate and niacinamide causes in increase of Cmax and AUC (bioavailability), thereby making it possible to make highly concentrated for-mutation of NεB29-hexadecandioyl-γ-Glu-(desB30) human insulin which is bioequivalent with a U200 preparation of the same insulin. The same observation has been made with the addition of treprostinil.
The soluble insulin preparation comprises NεB29-hexadecandioyl-γ-Glu-(desB30) human insulin in a concentration from 1800 nmol/ml to 4200 nmol/ml. In some embodiments the concentration of said NεB29-hexadecandioyl-γ-Glu-(desB30) human insulin is from 2400 nmol/ml to 3600 nmol/ml or from 2700 nmol/ml to 3300 nmol/ml. In another embodiment the concentration of NεB29-hexadecandioyl-γ-Glu-(desB30) human insulin is about 3000 nmol/ml.
The term “about” as used herein is intended to mean plus or minus 10%, such as plus or minus 5%. Hence, the term “about 100 U” is from 90 U to 110 U.
The soluble insulin preparation comprises zinc which may be added as e.g. zinc acetate or zinc chloride. The soluble preparations may comprise zinc ions in the range from 4.0 Zn/6Ins to 7.0 Zn/6Ins. In one embodiment the concentration of said zinc ions is from 4.0 Zn/6Ins to 6.0 Zn/6Ins. In another embodiment the concentration of said zinc ions is from 4.7 Zn/6Ins to 5.7 Zn/6Ins. In another embodiment the concentration of said zinc ions is from 5.0 Zn/6Ins to 6.0 Zn/6Ins. In yet another embodiment the concentration of said zinc ions is from 5.0 Zn/6Ins to 5.5 Zn/6Ins. In another embodiment the soluble insulin preparation according to the invention has a concentration of zinc ions of 5.0 Zn/6Ins. In another embodiment the soluble insulin preparation according to the invention has a concentration of zinc ions of 5.5 Zn/6Ins. In another embodiment the soluble insulin preparation according to the invention has a concentration of zinc ions of 6.0 Zn/6Ins.
The soluble insulin preparation according to the invention comprises niacinamide in a concentration from 110 mM to 220 mM or treprostinil in a concentration from 0.02 μg/ml to 1 μg/ml. In one embodiment the soluble insulin preparation comprises niacinamide. The soluble insulin preparation may in an embodiment comprises niacinamide in a concentration from 135 mM to 195 mM, or from 150 mM to 180 mM. In another embodiment the soluble preparation comprises niacinamide in a concentration from 110 mM to 140 mM, or from 190 mM to 220 mM. In another embodiment the soluble preparation comprises niacinamide in a concentration from 110 mM to 170 mM. In another embodiment the soluble preparation comprises niacinamide in a concentration from 150 mM to 220 mM.
In another embodiment the soluble preparation comprises niacinamide in a concentration of about 160 mM. In another embodiment the soluble preparation comprises niacinamide in a concentration of 161 mM. In another embodiment the soluble preparation comprises niacinamide in a concentration of about 200 nM. In another embodiment the soluble preparation comprises niacinamide in a concentration of 204 mM. In another embodiment the soluble preparation comprises niacinamide in a concentration of about 210 nM. In another embodiment the soluble preparation comprises niacinamide in a concentration of 211 mM.
In another embodiment the soluble insulin preparation comprises treprostinil. In another embodiment the soluble insulin preparation comprises treprostinil in a concentration from 0.02 μg/ml to 0.5 μg/ml, from 0.04 μg/ml to 0.3 μg/ml, from 0.05 μg/ml to 0.2 μg/ml or from 0.1 to 1 μg/ml. In another embodiment the soluble insulin preparation comprises treprostinil in a concentration of 0.1 μg/ml.
The soluble insulin preparation as described herein comprises citrate in a concentration from 6 mM to 40 mM. The term citrate is to be understood to include citrate salt as well as citric acid. In one embodiment the soluble insulin preparations comprises citrate in a concentration from 15 mM to 30 mM, from 6 mM to 20 mM or from 20 mM to 40 mM. The soluble insulin preparation as described herein comprises citrate in a concentration of 6 mM. The soluble insulin preparation as described herein comprises citrate in a concentration of 10 mM. The soluble insulin preparation as described herein comprises citrate in a concentration of 20 mM.
The soluble insulin preparations of the present invention have a pH in the range from 7.0 to 8.0. In one embodiment the pH is from 7.2 to 8.0, from 7.4 to 7.8, from 7.0 to 7.5, from 7.4 to 8.0 or from 7.4 to 7.8. In another embodiment the pH of the soluble insulin preparation is pH 7.6.
Since soluble insulin preparations are sterile liquids they may comprise a preservative or they may be free from any preservative. In one embodiment the soluble insulin preparation according to the invention further comprising a phenolic preservative or a mixture of phenolic preservatives. In one embodiment said phenolic preservative is phenol. In another embodiment preservative is a mixture of phenolic preservatives, such as a mixture of phenol and m-cresol. In another embodiment the preservative is a mixture of phenol and m-cresol and the concentration of phenol is from 1.3 mg/ml to 2.0 mg/ml and the concentration of m-cresol is from 1.5 mg/ml to 2.3 mg/ml. In another embodiment the preservative is a mixture of phenol and m-cresol and the concentration of phenol is 1.8 mg/ml and the concentration of m-cresol is 2.05 mg/ml.
In some embodiments the soluble insulin preparation comprises a further isotonicity agent. In one embodiment said isotonicity agent is glycerol. The need for the addition of such an isotonicity agent will be apparent when the concentrations of the other constituents of the soluble insulin preparation are determined. In another embodiment the soluble insulin preparation comprises no further isotonicity agent.
In one embodiment the soluble insulin preparation comprises no further buffering agent.
In an aspect the invention is provided a method of reducing the blood glucose level in a mammal by administering to a subject in need of such treatment a therapeutically effective dose of a soluble insulin preparation as described herein.
In an aspect the invention is provided a method for the treatment of diabetes mellitus in a subject comprising administering to said subject a soluble insulin preparation as described herein.
In another aspect is provided a soluble insulin preparation for use in the treatment or prevention of hyperglycemia including stress induced hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, and burns, operation wounds and other diseases or injuries where an anabolic effect is needed, myocardial infarction, stroke, coronary heart disease and other cardiovascular disorders and treatment of critically ill diabetic and non-diabetic patients.
The insulin preparations of the invention may be prepared as is known in the art, e.g. as described in the Examples.
The invention will be summarized in the following embodiments:
The aim of this study was to compare Tresiba® U100, Tresiba® U200 and a similar formulation of degludec at 3000 nmol/L (U500), evaluate the effect of replacing the combination of phenol and m-cresol by phenol only, evaluate the effect of reducing relative zinc concentration (Zn/6Ins), evaluate the effect of adding niacinamide, and furthermore evaluate effect of adding citrate by a pig study. Beforehand the formulations should be tested for physical and chemical stability by an in use test and storage.
Insulin degludec was added to water to about 8 mM and dissolved. pH was adjusted by 0.2N NaOH to pH 7.6 and the stock solution was sterile filtered and content was determined. To insulin degludec stock solution were added in mentioned order excess of water, glycerol (20% (w/vol)), phenol (500 mM), m-cresol (160 mM), niacinamide (1000 mM), trisodium citrate (100 mM), and zinc acetate (20 mM, pH ad 6.6 by hydrochloric acid). Zinc acetate was added gradually. pH was then adjusted to 7.6 by 0.2N sodium hydroxide/hydrochloric acid, volume adjusted with water and the formulation sterile filtered. The formulations were filled in 3 mL cartridge for insulin pen.
A subset of cartridges were in use tested at 30° C. for 12 weeks adding 25 μL air to 1 mL formulation in each cartridge and rotating 1 min/day. The cartridges were examined regularly by visual inspection and no change or particle formation was found for any of the for-mutations during the period. The formulations were tested for chemical stability by determination of covalent high molecular weight products (HMWP) during 12 weeks at 30° C. and all found stable and about the same low covalent dimer formation rate.
Sixteen female domestic pigs (mean body weight approximately 80 kg) were fasted overnight prior to the studies and fed 8 hours after dosing of the test insulin formulations. To investigate different formulations of insulin degludec, each pig was to receive the formulations described in Table 1 in a balanced, non-randomized cross-over design according to the schedule outlined in Table 2.
15, 16 #
15, 16 #
15, 16 #
One pig had to be replaced during the study, so in total 17 pigs were studied.
Pigs were dosed in the morning and samples were drawn as indicated in
Data analysis was performed on AUCs derived by non-compartmental analysis (Phoenix software) and since formulations differed slightly from the intended concentration, dose-normalized AUCs (AUC/dose) were calculated.
Results
Comparison of formulations A and B illustrates that the PK curve for formulation B is flatter than that of the U100 formulation, but the total dose normalized AUCs do not differ appreciably (
Pigs exhibit an early peak in absorption of insulin degludec that is not seen in humans. The estimation and comparison of Cmax is therefore associated with uncertainty. Considering the second peak (maximal exposure that occurs around 10-12 hours after dosing), we observed that the reduction in formulation F is approximately 38% to that of formulation B. Cmax was increased in formulation G (only 10% reduction compared to formulation B) and in formulation H (only 21% reduction compared to formulation B). These differences can be seen in
Reduced relative bioavailability and reduced late Cmax are observed when up-concentrating insulin degludec from 1200 nmol/ml (U200) to 3000 nmol/ml (U500) to an extent that the U500 formulation is not bioequivalent to the U200 formulation and where higher doses of a U500 formulation compared to a U200 formulation would be needed to give equivalent glucose lowering effects. We have solved this problem by showing that both citrate and niacinamide almost restore the AUC and partially the Cmax and we are guided to test the combination of citrate and niacinamide to make a U500 formulation that is bioequivalent to U200 Tresiba® where the same dose of a U500 formulation and U200 Tresiba® will give equivalent glucose lowering effects.
The aim of this study was to compare degludec U200 and a similar formulation of degludec at 3000 nmol/L (U500), evaluate the effect of citrate at two levels, evaluate the effect of niacinamide added to isotonicity and omitting glycerol, evaluate effect of two combinations of citrate and niacinamide and finally test effect of adding treprostinil by an additional pig study. Beforehand the formulations should be tested for physical and chemical stability by an in use test and storage.
Insulin degludec was added to water to about 7 mM and dissolved. pH was adjusted by 0.2N NaOH to pH 7.8 and the stock solution was sterile filtered and content was determined. To degludec stock solution were added in mentioned order excess of water, glycerol (20% (w/vol)), phenol (500 mM), cresol (160 mM), zinc acetate (20 mM, pH ad 6.6 by hydrochloric acid, added gradually), niacinamide (1000 mM), trisodium citrate (300 mM), and treprostinil (10 μg/mL). pH was then adjusted to 7.6 by 0.2N sodium hydroxide/hydrochloric acid, volume adjusted with water and the formulation sterile filtered. The formulations were filled in 3 mL cartridge for insulin pen.
The study was performed in 16 female LYD pigs of SPF origin delivered from Lars Jonsson, Hillerødvej 70, Lynge, Denmark. At start of the acclimatization period, the body weight of the pigs was in the range of 59.5-68.5 kg, with an expected minimum weight of 70 kg on the first dosing day. Four extra animals were available during the study and three of these were included due to catheter malfunction and/or infection.
Animals were fasted overnight prior to the studies and fed 8 hours after dosing of the test insulin formulations. To investigate different formulations of insulin degludec, each pig was to receive the formulations described in Table 4 in a balanced, non-randomized cross-over design according to the schedule outlined in Table 5.
Three of the four extra animals were used to replace animals with malfunctioning catheters, so in total 19 pigs were studied. A total of seven dosings were not performed due to malfunctioning injection catheters. One animal from group 8 was omitted from the data analysis since sampling in that animal was not possible on that day beyond 150 min after insulin dosing.
Results:
Pigs exhibit an early peak in absorption of insulin degludec that is not seen in humans. The estimation and comparison of Cmax is therefore associated with uncertainty. For clarity,
We note that when adding both niacinamide and citrate to the formulation, it is possible to tune both the AUC and the late Cmax to match the values in the degludec U200 formulation close enough that a degludec U500 formulation with niacinamide and citrate concentrations in the formulation space we have explored can be demonstrated to be bioequivalent to Tresiba® U200 in a clinical trial.
Example 4 illustrates that by appropriately chosen combinations of citrate and niacinamide in U500 formulations of insulin degludec, it is possible to match both Cmax and AUC to those of a U200 degludec formulation thereby demonstrating that it is possible to make a U500 formulation of insulin degludec that is bioequivalent to Tresiba® U200.
| Number | Date | Country | Kind |
|---|---|---|---|
| 19185958 | Jul 2019 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2020/069512 | 7/10/2020 | WO |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2021/009027 | 1/21/2021 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 3528960 | Haas | Sep 1970 | A |
| 3868358 | Jackson | Feb 1975 | A |
| 3907676 | Jorgensen | Sep 1975 | A |
| 4476118 | Brange et al. | Oct 1984 | A |
| 4652548 | Chance et al. | Mar 1987 | A |
| 4669430 | Reinold et al. | Jun 1987 | A |
| 4764592 | Massey et al. | Aug 1988 | A |
| 4876322 | Budde et al. | Oct 1989 | A |
| 4983658 | Kress et al. | Jan 1991 | A |
| 5008241 | Markussen et al. | Apr 1991 | A |
| 5177058 | Dorschug | Jan 1993 | A |
| 5382574 | Jorgensen | Jan 1995 | A |
| 5605884 | Lee et al. | Feb 1997 | A |
| 5646242 | Baker et al. | Jul 1997 | A |
| 5750497 | Havelund et al. | May 1998 | A |
| 5830999 | Dunn | Nov 1998 | A |
| 5866538 | Norup et al. | Feb 1999 | A |
| 5898067 | Balschmidt et al. | Apr 1999 | A |
| 5905140 | Hansen | May 1999 | A |
| 6011007 | Havelund et al. | Jan 2000 | A |
| 6051551 | Hughes et al. | Apr 2000 | A |
| 6174856 | Langballe et al. | Jan 2001 | B1 |
| 6211144 | Havelund | Apr 2001 | B1 |
| 6221837 | Ertl et al. | Apr 2001 | B1 |
| 6251856 | Markussen et al. | Jun 2001 | B1 |
| 6335316 | Hughes et al. | Jan 2002 | B1 |
| 6451762 | Havelund et al. | Sep 2002 | B1 |
| 6451970 | Schaffer et al. | Sep 2002 | B1 |
| 6504005 | Fridkin et al. | Jan 2003 | B1 |
| 6620780 | Markussen et al. | Sep 2003 | B2 |
| 6652886 | Ahn et al. | Nov 2003 | B2 |
| 6869930 | Havelund et al. | Mar 2005 | B1 |
| 7229964 | Markussen et al. | Jun 2007 | B2 |
| 7402565 | Kjeldsen et al. | Jul 2008 | B2 |
| 7544656 | Sabetsky | Jun 2009 | B2 |
| 7615532 | Jonassen et al. | Nov 2009 | B2 |
| 7713929 | Steiner et al. | May 2010 | B2 |
| 8003605 | Bayer et al. | Aug 2011 | B2 |
| 8067362 | Kodra et al. | Nov 2011 | B2 |
| 8404645 | Schlein | Mar 2013 | B2 |
| 8691759 | Madsen et al. | Apr 2014 | B2 |
| 8722620 | Fynbo et al. | May 2014 | B2 |
| 8796205 | Jonassen et al. | Aug 2014 | B2 |
| 8828923 | Jonassen et al. | Sep 2014 | B2 |
| 8933021 | Hubalek et al. | Jan 2015 | B2 |
| 8962794 | Madsen et al. | Feb 2015 | B2 |
| 9034818 | Poulsen et al. | May 2015 | B2 |
| 9045560 | Madsen et al. | Jun 2015 | B2 |
| 9447163 | Mollerup et al. | Sep 2016 | B2 |
| 9481721 | Naver et al. | Nov 2016 | B2 |
| 9603904 | Johansen et al. | Mar 2017 | B2 |
| 9688737 | Madsen et al. | Jun 2017 | B2 |
| 9839579 | Weeks et al. | Dec 2017 | B2 |
| 9884094 | Johansen et al. | Feb 2018 | B2 |
| 10137172 | Johansen et al. | Nov 2018 | B2 |
| 10172922 | Christe et al. | Jan 2019 | B2 |
| 10925931 | Akers et al. | Feb 2021 | B2 |
| 11167035 | Havelund et al. | Nov 2021 | B2 |
| 20010036916 | Brader | Nov 2001 | A1 |
| 20020045731 | Schaffer et al. | Apr 2002 | A1 |
| 20020155994 | Havelund et al. | Oct 2002 | A1 |
| 20030004096 | Boderke | Jan 2003 | A1 |
| 20030236196 | Kerwin et al. | Dec 2003 | A1 |
| 20040006000 | Langkjaer | Jan 2004 | A1 |
| 20040037909 | Kim et al. | Feb 2004 | A1 |
| 20040116345 | Besman et al. | Jun 2004 | A1 |
| 20040138099 | Draeger | Jul 2004 | A1 |
| 20050054818 | Brader et al. | Mar 2005 | A1 |
| 20050074866 | Grancha et al. | Apr 2005 | A1 |
| 20050222006 | Havelund et al. | Oct 2005 | A1 |
| 20050232899 | Balwani et al. | Oct 2005 | A1 |
| 20060183668 | Jonassen et al. | Aug 2006 | A1 |
| 20080076705 | Kodra et al. | Mar 2008 | A1 |
| 20090074882 | Havelund et al. | Mar 2009 | A1 |
| 20090137454 | Fynbo et al. | May 2009 | A1 |
| 20090186807 | Boderke | Jul 2009 | A1 |
| 20090239785 | Hubalek et al. | Sep 2009 | A1 |
| 20090312236 | Beals et al. | Dec 2009 | A1 |
| 20100009899 | Jonassen et al. | Jan 2010 | A1 |
| 20100167990 | Poulsen et al. | Jul 2010 | A1 |
| 20110152185 | Plum et al. | Jun 2011 | A1 |
| 20110230402 | Johansen et al. | Sep 2011 | A1 |
| 20110301081 | Becker et al. | Dec 2011 | A1 |
| 20120245085 | Naver et al. | Sep 2012 | A1 |
| 20130261051 | Johansen | Oct 2013 | A1 |
| 20140073759 | Mollerup et al. | Mar 2014 | A1 |
| 20140328943 | Havelund et al. | Nov 2014 | A1 |
| 20140349925 | Jonassen et al. | Nov 2014 | A1 |
| 20150126439 | Johansen et al. | May 2015 | A1 |
| 20150250857 | Andresen et al. | Sep 2015 | A1 |
| 20150273022 | Wilson et al. | Oct 2015 | A1 |
| 20160058840 | Johansen et al. | Mar 2016 | A1 |
| 20160296602 | Johansen | Oct 2016 | A1 |
| 20170056478 | Akers et al. | Mar 2017 | A1 |
| 20170165327 | Andresen et al. | Jun 2017 | A1 |
| 20170319664 | Johansen | Nov 2017 | A1 |
| 20180125946 | Johansen | May 2018 | A1 |
| 20190112348 | Madsen et al. | Apr 2019 | A1 |
| 20190160155 | Johansen | May 2019 | A1 |
| 20190194285 | Olsen et al. | Jun 2019 | A1 |
| 20190374614 | Skibsted et al. | Dec 2019 | A1 |
| 20210060132 | Andresen et al. | Mar 2021 | A1 |
| 20220152160 | Johansen | May 2022 | A1 |
| Number | Date | Country |
|---|---|---|
| 2011252127 | Feb 2014 | AU |
| 86101489 | Jan 1987 | CN |
| 88102311 | Nov 1988 | CN |
| 1829738 | Sep 2006 | CN |
| 101389650 | Dec 2006 | CN |
| 101454019 | Jun 2009 | CN |
| 104892749 | Sep 2015 | CN |
| 107920992 | Apr 2018 | CN |
| 1212679 | Mar 1966 | DE |
| 214826 | Mar 1987 | EP |
| 315968 | May 1989 | EP |
| 375437 | Jun 1990 | EP |
| 383472 | Aug 1990 | EP |
| 420649 | Apr 1991 | EP |
| 818204 | Jan 1998 | EP |
| 925792 | Jun 1999 | EP |
| 1153608 | Nov 2001 | EP |
| 884053 | Oct 2002 | EP |
| 1283051 | Feb 2003 | EP |
| 0894095 | May 2003 | EP |
| 0785713 | Sep 2003 | EP |
| 1595544 | Nov 2005 | EP |
| 2107069 | Oct 2009 | EP |
| 1951198 | Jun 2010 | EP |
| 2264065 | Dec 2010 | EP |
| 2264066 | Dec 2010 | EP |
| 2275439 | Jan 2011 | EP |
| 2287184 | Feb 2011 | EP |
| 2387989 | Nov 2011 | EP |
| 2389945 | Nov 2011 | EP |
| 2505593 | Oct 2012 | EP |
| 1042194 | Sep 1966 | GB |
| 1492997 | Nov 1977 | GB |
| B S36-11994 | Jul 1961 | JP |
| 38005689 | May 1963 | JP |
| B S38-5689 | May 1963 | JP |
| S5767548 | Apr 1982 | JP |
| H01254699 | Oct 1989 | JP |
| 02101022 | Apr 1990 | JP |
| H09502867 | Mar 1997 | JP |
| H10509176 | Aug 1998 | JP |
| 11-502110 | Feb 1999 | JP |
| 2000-501419 | Feb 2000 | JP |
| 2000-504732 | Apr 2000 | JP |
| 2000-515542 | Nov 2000 | JP |
| 2001-518915 | Oct 2001 | JP |
| 2001-518916 | Oct 2001 | JP |
| 2001-521004 | Nov 2001 | JP |
| 2001-521904 | Nov 2001 | JP |
| 2001521006 | Nov 2001 | JP |
| 2001-526225 | Dec 2001 | JP |
| 2002-527487 | Aug 2002 | JP |
| 2002-308899 | Oct 2002 | JP |
| 2002-543092 | Dec 2002 | JP |
| 2004-523589 | Aug 2004 | JP |
| 2006-511441 | Apr 2006 | JP |
| 2006-519253 | Aug 2006 | JP |
| 2007-523881 | Aug 2007 | JP |
| 2009-522231 | Jun 2009 | JP |
| 4808785 | Nov 2011 | JP |
| 4959005 | Jun 2012 | JP |
| 5026567 | Sep 2012 | JP |
| 5331071 | Oct 2013 | JP |
| 2016523807 | Aug 2016 | JP |
| 2160118 | Dec 2000 | RU |
| 2164520 | Mar 2001 | RU |
| 2006103280 | Sep 2007 | RU |
| 2317821 | Feb 2008 | RU |
| 2352581 | Apr 2009 | RU |
| 9109617 | Jul 1991 | WO |
| 9112817 | Sep 1991 | WO |
| 9307922 | Apr 1993 | WO |
| 9312812 | Jul 1993 | WO |
| 9507931 | Mar 1995 | WO |
| 9532730 | Dec 1995 | WO |
| 9610417 | Apr 1996 | WO |
| 9629344 | Sep 1996 | WO |
| 9704801 | Feb 1997 | WO |
| 9731022 | Aug 1997 | WO |
| 9802460 | Jan 1998 | WO |
| 9805361 | Feb 1998 | WO |
| 9842367 | Oct 1998 | WO |
| 9842368 | Oct 1998 | WO |
| 9847529 | Oct 1998 | WO |
| 9921573 | May 1999 | WO |
| 9921578 | May 1999 | WO |
| 9921888 | May 1999 | WO |
| 9922754 | May 1999 | WO |
| 9924071 | May 1999 | WO |
| 9932116 | Jul 1999 | WO |
| 0023098 | Apr 2000 | WO |
| 0043034 | Jul 2000 | WO |
| 0064940 | Nov 2000 | WO |
| 200149314 | Jul 2001 | WO |
| 02076495 | Oct 2002 | WO |
| 2003002136 | Jan 2003 | WO |
| 03013573 | Feb 2003 | WO |
| 03030829 | Apr 2003 | WO |
| 03053339 | Jul 2003 | WO |
| 030053339 | Jul 2003 | WO |
| 03094951 | Nov 2003 | WO |
| 03094956 | Nov 2003 | WO |
| 2004039392 | May 2004 | WO |
| 2004074481 | Sep 2004 | WO |
| 2004112828 | Dec 2004 | WO |
| 2005005477 | Jan 2005 | WO |
| 2005012347 | Feb 2005 | WO |
| 2005016365 | Feb 2005 | WO |
| 2005021022 | Mar 2005 | WO |
| 200547508 | May 2005 | WO |
| 2005063298 | Jul 2005 | WO |
| 2005089722 | Sep 2005 | WO |
| 2005117948 | Dec 2005 | WO |
| 2006008238 | Jan 2006 | WO |
| 2006020720 | Feb 2006 | WO |
| 2006023665 | Mar 2006 | WO |
| 0651103 | May 2006 | WO |
| 2006053906 | May 2006 | WO |
| 2006079019 | Jul 2006 | WO |
| 2006082204 | Aug 2006 | WO |
| 2006082205 | Aug 2006 | WO |
| 2007041481 | Apr 2007 | WO |
| 07074133 | Jul 2007 | WO |
| 2007074133 | Jul 2007 | WO |
| 2007096431 | Aug 2007 | WO |
| 2007121256 | Oct 2007 | WO |
| 2007128815 | Nov 2007 | WO |
| 2007128817 | Nov 2007 | WO |
| 07135117 | Nov 2007 | WO |
| 2008034881 | Mar 2008 | WO |
| 2008132224 | Nov 2008 | WO |
| 2008152106 | Dec 2008 | WO |
| 2009060071 | May 2009 | WO |
| 2009063072 | May 2009 | WO |
| 2010049488 | May 2010 | WO |
| 2011051486 | May 2011 | WO |
| 2011141407 | Nov 2011 | WO |
| 2012055967 | May 2012 | WO |
| 2012080320 | Jun 2012 | WO |
| 2012119007 | Sep 2012 | WO |
| 2013037754 | Mar 2013 | WO |
| 2013164375 | Nov 2013 | WO |
| 2018007172 | Jan 2018 | WO |
| 2018060735 | Apr 2018 | WO |
| 2019072818 | Apr 2019 | WO |
| Entry |
|---|
| Lane W. S. et al., High-dose insulin therapy: is it time for U-500 insulin?, Endocrine Practice, Jan./Feb. 2009, vol. 15, No. 1, pp. 71-79. |
| Segal A. R. et al., Use of concentrated insulin human regular (U-500) for patients with diabetes, American Journal of Health-System Pharmacy, Sep. 15, 2010, vol. 67, No. 18, pp. 1526-1535. |
| Valentine V., Don't Resist Using U-500 Insulin and Pramlintide for Severe Insulin Resistance, Clinical Diabetes, Apr. 2012, vol. 30, No. 2, pp. 80-84. |
| Obesity Society: Your weight and diabetes—http://www.obesity.org/resources-for/your-weight-and-diabetes.htm, (accessed Jul. 21, 2015). |
| Inzucchi S. E. et al., Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetologia, Apr. 20, 2012, vol. 55, No. 6, pp. 1577-1596. |
| Crasto W et al., Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus, Postgraduate Medical Journal, Feb. 10, 2009, vol. 85, No. 1002, pp. 219-222. |
| Heise T et al., Insulin Degludec Has a Two-Fold Longer Half-Life and a More Consistent Pharmacokinetic Profile Than Insulin Glargine, Diabetes, 2011, vol. 60(Suppl 1), LB11, (Abstract 37-LB), accessed Oct. 9, 2019. |
| Nosek L. et al., Ultra-Long-Acting Insulin Degludec Has a Flat and Stable Glucose-Lowering Effect, Diabetes 2011, 60(Suppl 1), LB14 (Abstract 49-LB), accessed Oct. 9, 2019. |
| Korsatko S. et al., Ultra-Long-Acting Insulin Degludec: Two Different Formulations (U100 and U200) Are Bioequivalent and Show Similar Pharmacodynamics, Diabetes 2011, 60(Suppl 1), A624 (Abstract 2349-PO), accessed Oct. 9, 2019. |
| Zinman B. et al., Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomized, open-label, phase 2 trial. The Lancet, Mar. 10, 2011, vol. 377, 924-931. |
| Heller S. et al., Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial, The Lancet, Apr. 2012, vol. 379, pp. 1489-1497. |
| Garber A. J. et al., Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial, The Lancet, Apr. 2012, vol. 379, pp. 1498-1507. |
| Declaration of Helsinki, Ethical principles for medical research involving human subjects., Journal of Indian Medical Association, Jun. 2009, vol. 107, No. 6, pp. 403-405. |
| Defining and Reporting Hypoglycemia in Diabetes: A report from the American Diabetes Association Workgroup on Hypoglycemia, Diabetes Care, 2005, vol. 28, No. 5, pp. 1245-1249. |
| HUMULIN® R Regular U-500 (Concentrated), Insulin Human Injection, USP (rDNA Origin), Eli Lilly and Company, Lilly USA, LLC, Indianapolis, IN 46285, USA, 1996. |
| Thornton S. et al., Intravenous overdose of insulin glargine without prolonged hypoglycemic effects, The Journal of Emergency Medicine, Sep. 2012, vol. 43, No. 3, pp. 435-437, XP002711646. |
| Zinman B. et al., Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once long), Diabetes Care, Dec. 2012, vol. 35, No. 12, pp. 2464-2471, XP9172018. |
| Rodbard H et al., Reduced risk of hypoglycaemia with insulin degludec vs insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: meta-analysis of five randomized trials. Presented as an oral at the AACE 21st Annual Scientific and Clinical Congress, Philadelphia, PA, May 23, 2012, (Abstract 241). |
| ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice, Journal of postgraduate medicine, 2001, vol. 47, No. 3, pp. 199-203. |
| Marcus A., Diabetes care—insulin delivery in a changing world, The Medscape Journal of Medicine, 2008, vol. 10, No. 5, 120. |
| Hoevelmann U. et al., Insulin degludec 200 U/ml is ultra-lang-acting and has a flat and stable glucose-lowering effect, Diabetologia, 2012, vol. 55, No. Suppl. 1, pp. S374-S375, XP002723769 & 48th Annual Meeting of the European-Association-For-The-Study-Of-Diabetes; Berlin, Germany; Oct. 1-5, 2012. |
| Wang F. et al., Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review, Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy, Jul. 2012, vol. 5, pp. 191-204, XP002723770. |
| Korsatko S. et al., Ultra-long-acting insulin degludec: bio-equivalence and similar pharmacodynamics shown for two different formulations (U100 and U200), Diabetologia, 2011, vol. 54, No. Suppl. 1, XP002723771, p. S427, & 47th Annual Meeting of the European-Association-For-The-Study-Of-Diabetes (EASD); Lisbon, Portugal; Sep. 12-16, 2011. |
| Havelund, S. et al., “The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin”, Pharmaceutical Research, 2004, vol. 21, No. 8, pp. 1498-1504. |
| Barnett, A.H., “A Review of Basal Insulins,” Diabet Med, 2003, vol. 20, No. 11, pp. 873-885. |
| Brussels: International Diabetes Federation, IDF Clinical Guidelines Task Force, Guideline for Management of Postmeal Glucose, 2007, pp. 1-32, http://www.idf.org/webdata/docs/Guideline_PMG_final.pdf. |
| Brussels: International Diabetes Federation, IDF Clinical Guidelines Task Force, Global Guideline for Type 2 Diabetes, 2005, pp. 1-82, http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf. |
| Irie et al., “Pharmacokinetics and Pharmacodynamics of Single Dose Insulin Detemir, Long-Acting Soluble Insulin Analogue Compared to NPH Insulin in Patients With Type 1 Diabetes Mellitus”, J Clin Ther Med, 2007, vol. 23, No. 5, pp. 349-356. |
| Schlichtkrull, J., “Insulin Crystals”, Acta Chemica Scandinavica, 1956, vol. 10, No. 9, pp. 1455-1458. |
| Vajo et al., “Genetically Engineered Insulin Analogs: Diabetes in the New Millennium,” Pharma Rev, 2000, vol. 52, No. 1, pp. 1-9. |
| Whittingham, J.L. et al., “Crystallographic and Solution Studies of N-Lithocholyl Insulin: A New Generation of prolonged-Acting Human Insulins”, Biochemistry, 2004, vol. 42, pp. 5987-5995. |
| Brange, J et al Diabetic Medicine Neutral Insulin Solutions Physically Stabilized by Addition of ZN2+, 1986, vol. 3, No. 6, pp. 532-536. |
| Jonassen, I. et al., Pharmaceutical Research 2006, vol. 23, No. 1, pp. 49-55. |
| Yasuhiko Iwamoto, “New Insulin Formulation,” Annual Review Increation and Metabolism 2000, 9 pages. |
| Nathan, D. M. et al., “Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy,” Diabetes Care, 2008, vol. 31, No. 1, pp. 173-175. |
| Heise, T. et al., “Towards Peakless, Reproducible and Long-Acting Insulins. An Assessment of the Basal Analogues Based on Isoglycaemic Clamp Studies,” Diabetes Obes Metab, 2007, vol. 9, No. 5, pp. 648-659. |
| Hinds et al., “PEGylated insulin in PLGA microparticles. In vivo and in vitro analysis,” Journal of Controlled Release, 2005, vol. 104, No. 3, pp. 447-460. |
| Heller. S R, Current Medical Research and Opinion, “Insulin Analogues”, 2002, vol. 18, No. 1, pp. 40-47. |
| R. Cuddihy et al., Diabetologia, “Once-Daily Use of a New Generation Ultra-Long Acting Basal Insulin With a Bolus Boost in Insulin-Naïve People With Type 2 Diabetes: Comparison With Insulin Glargine”, Sep. 2010, vol. 53, No. 1, pp. S389. |
| Samuel et al. “Studies on the immunogenicity of protamines in humans and experimental animals by means of a micro-complement fixation test.” Clin. Exp. Immunol. vol. 33: pp. 252-260. 1978. |
| Kurtz et al. “Circulating IgG antibody to protamine in patients treated with protamine-insulins.” Diabetologica. vol. 25: pp. 322-324. 1983. |
| Definition of Moiety From http://dictionary.reference.com/browse/moiety, Aug. 26, 2010, pp. 1-3. |
| I. Jonassen et al., “Insulin Degludec: Multi-Hexamer Formation is the Underlying Basis for This New Generation Ultra-Long Acting Basal Insulin”, Diabetologia, Sep. 2010, vol. 53, No. 1, pp. S388. |
| R. Cuddihy et al., “Once-Daily Use of a New Generation Ultra-Long Acting Basal Insulin With a Bolus Boost in Insulin-Naïve People With Type 2 Diabetes: Comparison With Insulin Glargine”. Diabetologia, Sep. 2010, vol. 53, No. 1, pp. S389. |
| American Diabetes Association, Standards of Medical Care in Diabetes Jan. 2012, Diabetes Care 2012, vol. 35 (Suppl 1), pp. S11-S63. |
| American Diabetes Association. Insulin administration. Diabetes Care, Jan. 2012 , vol. 35, No. 1, pp. S1-S2. |
| American Diabetes Association. Standards of Medical Care in Diabetes—2014. Diabetes Care. 2014, vol. 37 Suppl 1, pp. S14-S80. |
| Anderson RM et al. Patient empowerment: results of a randomized controlled trial. Diabetes Care. 1995, vol. 18, No. 7 pp. 943-949. |
| Barnett et al: Dosing of insulin glargine in the treatment of type 2 diabetes ,Clinical Therapeutics, 2007 vol. 29, No. 6,,pp. 987-999. |
| Benjamin EM. Self-monitoring of blood glucose: the basics. Clinical Diabetes. 2002, vol. 20, No. 1, pp. 45-47. |
| Schnell et al., “Consensus statement on self-monitoring of blood glucose in diabetes,” Diabetes, Stoffwechsel und Herz, Jul. 2009, vol. 4, pp. 285-289. |
| Selvin et al., ““Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus,”” Ann. Intern. Med., Sep. 2004, vol. 141, pp. 421-431. |
| The Diabetes Control and Complications Trial Research Group, “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus,” N Engl J Med, 1993, vol. 329, No. 14, pp. 977-986. |
| UK Prospective Diabetes Study (UKPDS) Group, “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33),” Lancet, 1998, vol. 352, pp. 837-853. |
| Yeaw et al., “Cost of self monitoring of blood glucose in Canada among patients on an insulin regimen for diabetes,” Diabetes Ther. Epub Jun. 27, 2012, vol. 3, pp. 1-17. |
| Yeaw et al., “Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes,” J Manag. Care Pharm., Jan. Feb. 2012, vol. 18, pp. 21?32. |
| Yeaw et al., “Self-monitoring blood glucose test strip utilization in Canada,” Diabetes, Jun. 2012, vol. 61(Suppl 1), p. A35. |
| Lajara R, et al. Healthcare professional and patient perceptions of a new prefilled insulin pen versus vial and syringe. Expert Opinion on Drug Delivery, Sep. 2012, vol. 9, pp. 1181-1196. |
| Bailey T, et al. FlexTouch® for the delivery of insulin: technical attributes and perception among patients and healthcare professionals. Expert Review of Medical Devices, 2012, vol. 9, pp. 209-217, published online Jan. 9, 2014. |
| Anthony H. Barnett, Diabetic Medicine, A Review of Basal Insulins, 2003, vol. 20, No. 11, pp. 873-885. |
| Heise, T. et al., Diabetes, Obesity and Metabolism, Towards Peakless, Reproducible and Long-Acting Insulins. An Assessment of the Basal Analogues Based on Isoglycaemic Clamp Studies, 2007, vol. 9, No. 5, pp. 648-659. |
| IDF Clinical Guidelines Task Force, Brussels: International Diabetes Federation 2005, Global Guideline for Type 2 Diabetes, 2005. |
| IDF Clinical Guidelines Task Force, Brussels: International Diabetes Federation 2007, Guideline for Management of Postmeal Glucose, 2007. |
| Nathan, D. M. et al., Diabetes Care, Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy, 2008, vol. 31, No. 1, pp. 173-175. |
| Talboys Catalog, 2008 Laboratory Equipment Catalog, Talboys by Troemner, 122 pages (2008). |
| Heise et al “Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin an Insulin Glargine in People with Type 1 Diabetes” Diabetes, 2004, vol. 53, pp. 1614-1620. |
| Novo Nordisk, Levemir Product Information, Jun. 16, 2005. 42 pages. |
| “America Pink”, http://america.pink/insulin-degludec_2091149.html, downloaded Aug. 24, 2016. |
| L. Heinemann and J. H. Anderson Jr. Diabetes Technol Ther 6 (5):698-728, 2004. |
| Living with Diabetes, available at http://www.diabetes.org/living-with-diabetes/treatment-and-care/medication/?loc=lwd-slabnav, accessed on Jan. 5, 2017. |
| WebMD “What is a unit of insulin,” available at http://answers.webmd.com/answers/1196453/what-is-a-unit-of-insulin, accessed Nov. 8, 2018. |
| Heise et al., “Insulin Degludec 200 U/mL is Ultra-Long Acting and Has a Flat and Stable Glucose-Lowering Effect,” Canadian Journal of Diabetes, Oct. 2012, vol. 36, No. 5, p. S13. |
| Springer et al., “Management of Type 2 Diabetes Mellitus in Children and Adolescents”, Pediatrics, Feb. 2013, vol. 131, No. 2, pp. e648-e664. |
| Heise et al., “Ultra-Long-Acting Insulin Degludec has a Flat and Stable Glucose-Lowering Effect in Type 2 Diabetes,” Diabetes, Obesity and Metabolism, Jun. 2012, vol. 14, pp. 944-950. |
| Heller et al., “Insulin Degludec, an Ultra-Longacting Basal Insulin, Versus Insulin Glargine . . . : a Phase 3, Randomized, Open-Label, Treat-to-Target Non-Inferiority Trial,” The Lancet, Apr. 2012, vol. 379, pp. 1489-1497. |
| Tambascia et al., “Degludec: the new ultra-long insulin analogue,” Diabetology Metabol. Synd., Jun. 2015, vol. 7, pp. 1-7. |
| Brange “Stability of Insulin”, 1994, Kluwer Academic Publishers BV, pp. 30-31. |
| Birkeland et al.“Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.” Diabetes Care, Mar. 2011, vol. 34, No. 3, p. 661-665. |
| Briscoe et al.,“Hypoglycemia in type 1 and type 2 diabetes: physiology, pathophysiology, and management.” Clinical diabetes, Jul. 2006, vol. 24, No. 3, pp. 115-121. |
| U.S. Appl. No. 16/463,594, filed May 23, 2019. |
| Le Tourneau, et al., “Dose escalation methods in phase 1 cancer clinical trials.” JNCI: Journal of the National Cancer Institute, May 2009, vol. 101, No. 10, pp. 708-720. |
| American Diabetes Association, “Standards of Medical Care in Diabetes—2012,” Diabet. Care., 2012, vol. 35(Suppl 1), pp. S11-S63. |
| American Diabetes Association, “Introduction,” Diabetes Care, Jan. 2012, vol. 35(Suppl. 1), pp. S1-S2. |
| American Diabetes Association, “Standards of Medical Care in Diabetes—2014,” Diabetes Care, Jan. 2014, vol. 37, Suppl. 1. |
| American Diabetes Association, “Insulin Administration,” Diabetes Care, Jan. 2002, vol. 25(suppl 1), pp. S112-S115. |
| Anderson et al., “Patient empowerment: results of a randomized controlled trial,” Diabetes Care, Jul. 1995, vol. 18, No. 7, pp. 943-949. |
| Benjamin EM, “Self-monitoring of blood glucose: the basics,” Clin Diabetes, Jan. 2002, vol. 20, No. 1, pp. 45-47. |
| Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Canadian Diabetes Association, Can J Diabetes, Sep. 2008; vol. 32(Suppl 1), pp. S1-S201. |
| Davies et al., “Improvement of glycemic control in subjects with poorly controlled type 2 diabetes,” Diabet. Care., Jun. 2005, vol. 28, pp. 1282-1288. |
| Duckworth et al., “Glucose control and vascular complications in veterans with type 2 diabetes,” N Engl J Med, 2009, vol. 360, pp. 129-139. |
| Gerstein et al., “A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study,” Diabet. Med., May 2006, vol. 23, No. 7, pp. 736-742. |
| Holman et al., “10-year follow-up of intensive glucose control in type 2 diabetes,” N Engl J Med, 2008, vol. 359, pp. 1577-1589. |
| Holman et al., “A practical guide to basal and prandial insulin therapy,” Diabet. Med., Jan. 1985, vol. 2, No. 1, pp. 45-53. |
| International Diabetes Federation Clinical Guidelines Task Force, “Global Guideline for Type 2 Diabetes,” 2005. |
| Inzucchi et al., “Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD),” Diabetes Care. Jun. 2012, vol. 35, pp. 1364-1379. |
| Kulzer et al., “Effects of self-management training in type 2 diabetes: a randomized, prospective trial,” Diabet. Med., Feb. 2007, vol. 24, pp. 415-423. |
| LANTUS® (insulin glargine [rDNA origin] injection), Sanofi-aventis U.S. LLC, Bridgewater, NJ, USA; 2007, Health Care Professional, Dosing & Titration, accessed Jan. 17, 2019. |
| Liebl et al., “Direct costs and health-related resource utilisation in the 6 months after insulin initiation in German patients with type 2 diabetes mellitus in 2006: INSTIGATE study,” Curr Med Res Opin, Jul. 2008, vol. 24, No. 8, pp. 2349-2358. |
| Meneghini et al., “The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes—results of the randomized, controlled PREDICTIVETM 303 study,” Diabet. Obes. Metab., Oct. 2007, vol. 9, pp. 902-913. |
| Nathan et al., ““Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes,”” N Engl. J Med., Dec. 2005, vol. 353, No. 25, pp. 2643-2653. |
| Nathan et al., “Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes,” Diabetes Care, 2008, vol. 31, No. 1, pp. 173-175. |
| Norris et al., “Self-management education for adults with type 2 diabetes: a meta-analysis on the effect of glycemic control,” Diabetes Care, Jul. 2002, vol. 25, pp. 1159-1171. |
| Ohkubo et al., “Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study,” Diabetes Res. Clin. Pract., 1995, vol. 28, pp. 103-117. |
| Patel et al. “Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes,” N Engl. J Med, 2008, vol. 358, pp. 2560-2572. |
| Peyrot et al., “Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy Study,” Diabet. Obes. Metab., Jun. 2012, vol. 14, pp. 1081?1087. |
| Peyrot et al., “Insulin adherence behaviors and barriers in the multinational Global Attitudes of Patients and Physicians in insulin therapy study,” Diabet. Med., Feb. 2012, vol. 29, pp. 682?690. |
| Philis-Tsimikas et al, Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use), Advances in Therapy, Jun. 2013, vol. 30, No. 6, pp. 607-622. |
| Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association. Canadian Journal of Diabetes. 2008, vol. 32(Suppl 1)pp. S1-S201. |
| Davies M, et al.. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes. Diabetes Care. 2005,vol. 28, No. 6, pp. 1282-1288. |
| Deutsch T et al.Utopia: A Consultation System for Visit-By-Visit Diabetes Management, Medical Informatica. Taylor and Francis.; Basingstoke. GB, 1996, vol. 21, No. 4, pp. 345-358. |
| Duckworth W. et al.Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes, The new england journal o f medicine, Jan. 2009, vol. 360, pp. 129-139. |
| Gerstein H C et al. A randomized trial of adding insulin glargine vs.avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia treatment) Study, Diabetic Medicines, 2006, vol. 23, No. 7, pp. 736-742. |
| Holman RR et al.,10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes,The New England Journal of Medicine, 2008, vol. 359, pp. 1577-1589. |
| Holman RR et al.A practical guide to Basal and Prandial Insulin therapy, Diabetic Medicine, 1985, vol. 2, pp. 45-53. |
| International Diabetes Federation Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. 2005. Available at: http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf. Accessed Dec. 19, 2012. |
| Inzucchi SE et al.Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD),Diabetes care, Jun. 2012, vol. 35, pp. 1364-1379. |
| Iwamoto Yasuhi KO et al: Insulin degludec in Japanese patients with type 1 diabetes mellitus: A randomized controlled trial,Journal of Diabetes Investigation, Jan. 2013, vol. 4, No. 1, pp. 62-68. |
| Janka Hans U et al, Combination of oral antidiabetic agents with basal insulin; versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus, Journal of the American Geriatrics Society, 2007,vol. 55, No. 2, pp. 182-188. |
| Kulzer B, et al. Effects of self-management training in type 2 diabetes: a randomized, prospective trial. Diabetic Medicine. 2007, vol. 24, No. 4, pp. 415-423. |
| LANTUS® (insulin glargine [rDNA origin] injection). sanofi-aventis U.S. LLC, Bridgewater, NJ, USA; 2007. Health Care Professional. Dosing & Titration. Available at: http://www.lantus.com/hcp/titration.aspx. Accessed Nov. 13, 2012. |
| Liebl A, et al. Direct costs and health-related resource utilisation in the 6 months after insulin initiation in German patients with type 2 diabetes mellitus in 2006: INSTIGATE study. Current Medical Research Opinion 2008, vol. 24, No. 3, pp. 2349-2358. |
| Meneghini L et al., The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes-results of the randomized, controlled PREDICTIVE TM 303 study. Diabetes Obesity and Metabolism. 2007, vol. 9, pp. 902-913. |
| Nathan DM et al,Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes,The new england journal of medicine, 2005, vol. 353, No. 25, pp. 2643-2653. |
| Nathan DM et al.Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: Update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2008, vol. 31, No. 1, pp. 173-175. |
| Nathan DM et al.The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus, the Diabetes Control and Complications Trial Research Group, The New England Journal of medicine, 1993, vol. 329, No. 14, pp. 977-986. |
| Norris SL, et al. Self-management education for adults with type 2 diabetes: a meta-analysis on the effect of glycemic control. Diabetes Care, 2002, vol. 25, No. 7, pp. 1159-1171. |
| Ohkubo Y et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study, Diabetes Research and Clinical Practice, 1995, vol. 28, No. 2 pp. 103-117. |
| Peyrot M, et al. Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy Study. Diabetes Obesity and Metabolism, Dec. 2012, vol. 14, pp. 1081-1087. |
| Peyrot M, et al.. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in insulin therapy study. Diabetic Medcine, Jan. 2012, vol. 29, No. 5, pp. 682-689. |
| Philis-Tsimikas A et al.: Insulin degludec once-daily in type 2 diabetes:; Simple or step-wise titration (BEGIN: Once Simple Use), Advances in Therapy, Jun. 2013, vol. 30, No. 6, pp. 607-622. |
| Sakharova O V et al.Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with Type 2 diabetes uncontrolled by oral agents, Journal of Diabetes and Its Complications, Mar. 2012, vol. 26, No. 4, pp. 333-338. |
| Schnell O, et al. Consensus statement on self-monitoring of blood glucose in diabetes. Diabetes, Stoffwechsel und Herz, Jul. 2009, vol. 4, pp. 285-289. |
| Selvin E et al.,.Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in; Diabetes Mellitus, Annals of Internal medicine,2004, vol. 141, pp. 421-431. |
| The ADVANCE Collaborative Group, Patel A et al.Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes, The new England Journal of Medicine, 2008, vol. 358, pp. 2560-2572. |
| UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)., Lancet, 1998, vol. 352 (9131), pp. 837-853. |
| Yeaw J, et al. Cost of self-monitoring of blood glucose in Canada among patients on an insulin regimen for diabetes. Diabetes Therapeutics . Epub ,2012 vol. 3, No. 7, pp. 1-17 doi: 10.1007/s13300-012-0007-6. |
| Yeaw J, et al., Self-monitoring blood glucose test strip utilization in Canada, Diabetes, Jun. 2012, vol. 61(Suppl 1), p. A35. |
| Yeaw J, et al.. Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes. Journal of Managed Care Pharmacy, Jan./Feb. 2012, vol. 18, No. 1, pp. 21-32. |
| American Diabetes Association. Insulin administration. Diabetes Care. 2002 vol. 25: pp. S112-S115. |
| Heise T, et al.. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obesity and Metabolism Sep. 2012, vol. 14, pp. 859-864. |
| Heise T, et al. Insulin degludec 200 U/mL is ultra-long-acting and has a flat and stable glucose-lowering effect. Diabetes, Jun. 2012, vol. 61(Suppl. 1) p. A91. |
| World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects—Last amended by the 59th WMA General Assembly, Seoul. 2008. Available at: http://www.wma.net/en/30publications/10policies/b3/17c.pdf. Accessed Sep. 14, 2015. |
| International Conference on Harmonisation. ICH Harmonised Tripartite Guideline:Guideline for Good Clinical Practice. E6 (R1), Step 4. 1996. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1_Guideline.pdf. Accessed Sep. 14, 2015. |
| Niskanen L, et al. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clinical Therapeutics 2004, vol. 26 pp. 531-540. |
| Garg S, et al. Preference for a new prefilled insulin pen compared with the original pen. Current Medical Research & Opinion, Oct. 2011, vol. 27, pp. 2323-2333. |
| Garber AJ, et al; on behalf of the NN1250-3582 BEGINTM BB T2D trial investigators. Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGINTM Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet, Apr. 2012, vol. 379, pp. 1498-1507. |
| Zinman B, et al; on behalf of the NN1250-3579 BEGIN tm Once Long trial investigators. Insulin degludec versus insulin glargine in insulin-naïve patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN tm Once Long). Diabetes Care, Dec. 2012, vol. 35, pp. 2464-2471. |
| Bergenstal R, Bhargava A, Jain RK, et al; on behalf of the NN1250-3672 BEGIN TM Low Volume trial investigators. 200 U/ml insulin degludec improves glycemic control similar to insulin glargine with a low risk of hypoglycemia in insulin-naïve people with type 2 diabetes. Abstract 207. http://am.aace.com/2012/sites/all/files/abstract-061812.pdf. Accessed Jan. 19, 2013. |
| Onishi Y, et al. Superior glycaemic control with once daily insulin degludec/ insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled on oral drugs: a randomized, controlled phase 3 trial. Diabetes Obesity and Metabolism, Sep. 2013, vol. 15, pp. 826-832. |
| Rakel RE. Improving patient acceptance and adherence in diabetes management: a focus on insulin therapy. Advances in Therapy, Sep. 2009, vol. 26, pp. 838-846. |
| Ross SA, et al. Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Current Medical Research and Opinion, Sep. 2011, vol. 27(Suppl 3), pp. 13-20. |
| Reimer T, et al. Intuitiveness, instruction time, and patient acceptance of a prefilled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling study in patients with type 2 diabetes. Clinical Therapeutics. 2008, vol. 30, pp. 2252-2262. |
| Rubin RR et al.. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care. 2008 vol. 31 pp. 430-432. |
| Peyrot M and Rubin RR. Factors associated with persistence and resumption of insulin pen use for patients with type 2 diabetes. Diabetes Technology & Therapeutics, Jan. 2011, vol. 13, No. 1, pp. 43-48. |
| Oyer D,et al. Ease of use and preference of a new versus widely available pre-filled insulin pen assessed by people with diabetes, physicians and nurses. Expert Opinion on Drug Delivery, Sep. 2011, vol. 8, pp. 1259-1269. |
| Bailey T,et al Usability and preference evaluation of a prefilled insulin pen with a novel injection mechanism by people with diabetes and healthcare professionals. Current Medical Research and Opinion, Sep. 2011, vol. 27, pp. 2043-2052. |
| Nadeau DA,et al. Healthcare professional and patient assessment of a new prefilled insulin pen versus two widely available prefilled insulin pens for ease of use, teaching and learning. Current Medical Research and Opinion, 2012, vol. 28, No. 1, pp. 3-13, published online Dec. 2011. |
| Number | Date | Country | |
|---|---|---|---|
| 20220249619 A1 | Aug 2022 | US |
